Vaccine News and Research

Latest Vaccine News and Research

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Soldiers, farmers can have common chronic exposure to nerve impacting chemicals

Soldiers in war zones and farmers tending their fields can have in common chronic exposure to chemicals that impact their nerves.

19 Apr 2012

BuruliVac project getting closer to a vaccine

During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.

19 Apr 2012

U.S. delegation expresses support for two vaccination campaigns while in Haiti

"A campaign to introduce new childhood vaccines to Haiti will save tens of thousands of lives over the next decade, CDC Director Dr. Thomas Frieden told NPR's health blog 'Shots' at the end of a two-day tour of the beleaguered country," the blog reports.

19 Apr 2012

New passive vaccine reverses dangerous symptoms of cocaine overdose

Scientists are reporting development and successful testing in laboratory mice of a substance that shows promise for becoming the first antidote for cocaine toxicity in humans. According to a report in ACS' journal Molecular Pharmaceutics, the new so-called "passive vaccine" reversed the motor impairment, seizures and other dangerous symptoms of a cocaine overdose, which claims thousands of lives each year among users of the illicit drug.

19 Apr 2012

First specific antidote for cocaine toxicity

Scientists at The Scripps Research Institute have shown that an injectable solution can protect mice from an otherwise lethal overdose of cocaine. The findings could lead to human clinical trials of a treatment designed to reverse the effects of cocaine in case of emergency. Cocaine is involved in more than 400,000 emergency-room visits and about 5,000 overdose deaths each year in the United States.

19 Apr 2012

Scientists identify hypervirulent Salmonella bacteria

UC Santa Barbara researchers have discovered Salmonella bacteria that are up to 100 times more capable of causing disease. Their findings may help prevent food poisoning outbreaks that continue to plague public health and the food industry.

19 Apr 2012

1 in 5 Australians expect antibiotics for coughs and colds: New NPS campaign

The survey also revealed a plethora of misconceptions when it comes to antibiotics with only half of respondents knowing that bacteria are becoming resistant to antibiotics. Only 40% knew antibiotics should not be taken for viruses and many (40%) did not know that taking antibiotics when they’re not needed contributes to antibiotic resistance. More than half did not know resistance increases when you don’t complete the course as directed and in general, the youth audience had less knowledge.

18 Apr 2012

Nigerian Vaccine Summit an opportunity to translate political will into action

In this post in the Huffington Post Blog, Orin Levine, executive director of the International Vaccine Access Center (IVAC), reports on the Nigerian Vaccine Summit, where Nigeria's leaders will meet this week to discuss children's health in the country.

18 Apr 2012

Autologous HSPPC-96 vaccine clinically beneficial for GBM patients

Study results from a Phase II multicenter clinical trial tracking the impact that autologous heat shock protein-peptide vaccine (HSPPC-96) has on recurrent glioblastoma multiforme (GBM) patients showed that such a vaccine may be clinically beneficial.

18 Apr 2012

Large childhood immunization campaign begins in Haiti, with support from U.S., other international partners

Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.

18 Apr 2012

Gates Foundation, Brazilian health ministry form alliance to expand Grand Challenges in Global Health initiative

The Bill & Melinda Gates Foundation on Monday announced it has formed an alliance "with the Brazilian Ministry of Health in the latest expansion of the foundation's Grand Challenges in Global Health initiative," the Puget Sound Business Journal reports.

18 Apr 2012

New brain cancer vaccine with material from own tumors proves effective in clinical trial

A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

Allied Healthcare announces Coridon license to vector technology

Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.

17 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

Flu outbreak at veterans home

State Veterans' Affairs Commissioner Linda Schwartz told The Associated Press that the veterans were taken to Hartford Hospital after a number began complaining of flu-like symptoms. The 18 men live at the Connecticut State Veterans Home in either the Sgt. John L. Levitow Veteran's Health Center or a residential facility.

17 Apr 2012

Caring for wife with breast cancer can affect men's health

Caring for a wife with breast cancer can have a measurable negative effect on men's health, even years after the cancer diagnosis and completion of treatment, according to recent research.

17 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

Canadian docs recommend HPV vaccine for boys

Girls have had access to free HPV vaccinations for five years - administered to protect them against cervical cancer - and this week, the Canadian Cancer Advocacy Coalition called on provincial governments to pay for the vaccine for boys as well. In January, the National Advisory Committee on Immunization recommended HPV vaccination for males aged nine to 25.

16 Apr 2012